Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.46 |
| ▸ | ACHE | P22303 | 3/20 | 0.46 |
| ▸ | APP | P05067 | 2/20 | 0.46 |
| ▸ | CCR4 | P51679 | 1/20 | 0.45 |
| ▸ | PIP4K2C | Q8TBX8 | 2/20 | 0.41 |
| ▸ | JAK1 | P23458 | 2/20 | 0.40 |
| ▸ | JAK3 | P52333 | 2/20 | 0.40 |
| ▸ | STAT6 | P42226 | 1/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.37 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.37 |
| ▸ | NPR1 | P16066 | 3/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | MERTK | Q12866 | 1/20 | 0.35 |
| ▸ | INSR | P06213 | 1/20 | 0.34 |
| ▸ | NPM1 | P06748 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30092953 | 0.85 | ACHE (0.65) | BCHEACHEAPPCCR4NPR1 | |
| SCHEMBL20399736 | 0.85 | ACHE (0.65) | BCHEACHEAPPCCR4NPR1 | |
| SCHEMBL21542040 | 0.83 | BCHE (0.46) | BCHEACHEAPPPIP4K2CJAK1 | |
| SCHEMBL21542006 | 0.83 | PIP4K2C (0.46) | BCHEACHEAPPCCR4PIP4K2C | |
| SCHEMBL30092914 | 0.83 | CCR4 (0.43) | BCHEACHEAPPCCR4PIP4K2C | |
| SCHEMBL21541998 | 0.82 | BCHE (0.52) | BCHEACHEAPPCCR4PIP4K2C | |
| SCHEMBL30093063 | 0.82 | CCR4 (0.44) | BCHEACHEAPPCCR4PIP4K2C | |
| SCHEMBL21542045 | 0.80 | PIP4K2C (0.51) | BCHEACHEAPPCCR4PIP4K2C | |
| SCHEMBL21542060 | 0.79 | CCR4 (0.48) | BCHEACHEAPPCCR4PIP4K2C | |
| SCHEMBL26746864 | 0.75 | ACHE (0.63) | BCHEACHEAPPCCR4NPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545675-B2 | Anti-wolbachia pyrido[2,3-d]pyrimidine compounds | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2026-02-10 | — | — | US | disclosed |
| US-20240108629-A1 | AZAQUINAZOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING DIROFILARIA INFECTION IN A MAMMAL | LIVERPOOL SCHOOL TROPICAL MEDICINE (GB) | 2024-04-04 | — | — | US | disclosed |
| EP-4277631-A1 | AZAQUINAZOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING DIROFILARIA INFECTION IN A MAMMAL | Liverpool School of Tropical Medicine (GB) | 2023-11-22 | — | — | EP | disclosed |
| US-20230348460-A1 | ANTI-WOLBACHIA PYRIDO[2,3-d]PYRIMIDINECOMPOUNDS | THE UNIVERSITY OF LIVERPOOL (GB) | 2023-11-02 | — | — | US | disclosed |
| US-20230348460-A1 | ANTI-WOLBACHIA PYRIDO[2,3-d]PYRIMIDINECOMPOUNDS | THE UNIVERSITY OF LIVERPOOL (GB) | 2023-11-02 | — | — | US | disclosed |
| US-11518760-B2 | Anti-Wolbachia pyrido[2,3-d]pyrimidine compounds | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2022-12-06 | — | — | US | disclosed |
| WO-2022152918-A1 | AZAQUINAZOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING DIROFILARIA INFECTION IN A MAMMAL | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2022-07-21 | — | — | WO | disclosed |
| US-20190345157-A1 | COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-11-14 | — | — | US | disclosed |
| US-20190345157-A1 | COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545675-B2 | Anti-wolbachia pyrido[2,3-d]pyrimidine compounds | CBR1, CBR3, COX6C | BCHE 2784/4885ACHE 2483/4885APP 4837/4885 |
| US-20230348460-A1 | ANTI-WOLBACHIA PYRIDO[2,3-d]PYRIMIDINECOMPOUNDS | PWWP2B, WARS1, PNPO | BCHE 3860/4885ACHE 1710/4885APP 3897/4885 |
| US-20190345157-A1 | COMPOUNDS | ABCB11, LTC4S, AQP1 | BCHE 632/4885ACHE 297/4885APP 2829/4885 |
| US-11518760-B2 | Anti-Wolbachia pyrido[2,3-d]pyrimidine compounds | P2RX5, PNPO, P2RX3 | BCHE 3579/4885ACHE 1142/4885APP 4242/4885 |
| US-20240108629-A1 | AZAQUINAZOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING DIROFILARIA INFECTION IN A MAMMAL | AQP3, AQP1, AQP4 | BCHE 746/4885ACHE 686/4885APP 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.